Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Elderly Untreated Advanced NSCLC
NCT00137800Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2003
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Objective Response Rate at 2 years and Overall Survival. Started Feb 2003; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00137800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137800.